Patents by Inventor Johanne Kaplan

Johanne Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced anti-tumor immunity
    Patent number: 7014848
    Abstract: The present invention provides methods for inducing an antigen-specific immune response by administering allogeneic antigen-presenting cells to a subject. In another aspect, an effective amount of autologous antigen-presenting cells are co-administered to a subject.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: March 21, 2006
    Assignee: Genzyme Corporation
    Inventors: Johanne Kaplan, Abraham Scaria
  • Transgene expression systems
    Patent number: 6485720
    Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: November 26, 2002
    Assignee: Genzyme Corporation
    Inventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
  • Transgene expression systems
    Patent number: 6358507
    Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: March 19, 2002
    Assignee: Genzyme Corporation
    Inventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
  • Transgene expression systems
    Publication number: 20020028194
    Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.
    Type: Application
    Filed: August 8, 2001
    Publication date: March 7, 2002
    Inventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
  • Transgene expression systems
    Patent number: 6100086
    Abstract: The present invention relates to transgene expression systems, related pharmaceutical compositions, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA sequence encoding a transgene which codes for a desired product, expressibly contained within an adenovirus vector containing at least a portion of the E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or "E4 cassette") includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: August 8, 2000
    Assignee: Genzyme Corporation
    Inventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
  • Prolactin as a vaccine adjuvant
    Patent number: 5585099
    Abstract: The present invention relates to a composition for enhancing the immune response of an animal to an infectious disease vaccine wherein the composition comprises prolactin. Preferably, the composition is human prolactin and the animal to be vaccinated is, as well, human.The present invention further relates to a composition for enhancing the immune response of an animal to an infectious disease vaccine wherein the composition comprises prolactin cDNA. Human prolactin cDNA is preferred.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: December 17, 1996
    Assignee: Genzyme Corporation
    Inventors: Susan Richards, Johanne Kaplan, Richard Moscicki